Since the introduction of cephalothin in 1962 (1, 11) structural modification of the 7-aminocephalosporanic acid nucleus has provided analogues for clinical use with improved physical-chemical, pharmacologic, or antimicrobial properties (3-5, 9, 10) . In particular, the need for cephalosporins suitable for oral administration has been recognized. Cephaloglycin and cephalexin were the first acid-stable derivatives suitable for oral administration; in addition, cephradine was introduced in 1974. However, cephaloglycin is unstable at alkaline pH and is rapidly metabolized in the liver to the less potent desacetylcephaloglycin; therefore, oral administration results in low serum antibacterial activity (5, 12) . This has prohibited its use in systemic infections and confined it to treatment of urinary tract infections. In contrast, cephalexin is totally absorbed after oral administration and is excreted unchanged by the kidney (4, 8) . Although it possesses desirable pharmacological properties, cephalexin has less antimicrobial activity than cephalothin, cephaloridine, cefazolin, or cephaloglycin (4, 8) . Despite this limitation, cephalexin has been used extensively since more active oral cephalosporins are unavailable. A recently licensed analogue, cephradine, differs only slightly from cephalexin in its antimicrobial activity and pharmacological properties (12, 5) , and it can be administered orally, intramuscularly, or intravenously.
BL-S640 17-D-alpha-amino-alpha- [4-hydroxy- phenylJacetamido [3-(1H-1,2,3-triazol-5-thio)-methyl]-3-cephem-4-carboxylic acidi is a new semisynthetic cephalosporin (2) . The structure is shown in Fig. 1 . A water-soluble preparation is available as a propylene glycolate, since aqueous solutions are unstable and have been shown to lose up to 50% of antimicrobial activity at pH 7.4 in several hours. (They are stable, however, at -16 C for up to 10 days.) In anticipation that this cephalosporin analogue may be suitable as an oral preparation, its in vitro antimicrobial spectrum and activity are reported. Cross-resistance study. Representative grampositive and/or gram-negative microorganisms were selected to study cross-resistance between BL-8640 and cephalothin, cephalexin, or cefazolin. First, selected strains with demonstrated susceptibility to each of the cephalosporins were inoculated into serially diluted concentrations of BL-S640 as previously described. Those microorganisms surviving the highest concentration of BL-S640 after overnight incubation were re-inoculated into appropriate broth. After another 18 to 20 h of incubation, these microorganisms were used to prepare the inoculum for similar tubes containing the serially diluted BL-S640. After seven such passages in BL-S640, determinations of MICs for each strain were repeated to BL-S640, cephalexin, and cephalothin. In addition, cefazolin was included in cross-resistance studies with strains of Klebsiella. To test the stability of the resistance acquired after serial passage in BL-S640, all strains were subcultured for 10 days on Mueller-Hinton media without added antibiotic. Change in antibiotic resistance was screened for by daily disk susceptibility tests to cephalothin and documented by the determination of MICs to all of the selected cephalosporins.
RESULTS
Antimicrobial spectrum. Most strains of Escherichia coli and Klebsiella were susceptible to low concentrations of BL-S640; 30 of 35 strains (85%) were inhibited at concentrations of .12.5 pg of BL-S640 per ml (Table 1) . However, the remaining five strains were resistant at concentrations of >50 pAg of BL-S640 per ml. Strains of Citrobacter were inhibited at concentrations of .6.25 pAg of BL-S640 per ml. Strains of Serratia and Pseudomonas uniformly required concentrations of > 50 ug of BL-S640 per ml for inhibition of growth (Table 1) . Enterobacter and Providencia frequently required > 12.5 pg of BL-S640 per ml to inhibit growth. The MICs of Proteus strains were separated sharply into those < 1.60 pg of BL-S640 per ml and those .12.5 pg of BL-S640 per ml. However, the susceptibility of the 14 strains varied and did not correlate with indole production.
Strains of methicillin-susceptible staphylococci had a median MIC and MBC of 3.13 and 12.5 pg of BL-S640 per ml, respectively (Table  2 ). In contrast, methicillin-resistant staphylococci were uniformly resistant, requiring concentrations of . 25 ,g BL-S640 per ml to inhibit growth. Streptococci were uniformly susceptible (Table 4) . The larger inoculum resulted in a three-to sixfold-higher MIC in Mueller-Hinton broth and a fourfold-higher MIC in nutrient broth. In addition, inhibitory concentrations were noted to be from two-to fourfold less in nutrient than in Mueller-Hinton broth with the same inocula against the same organism. The exceptions were in the study of two strains of Klebsiella, where inhibitory concentrations for BL-S640 were higher in nutrient than in Mueller-Hinton broth (Table 4) .
Cross-resistance and comparison of potency to other cephalosporins. The antimicrobial potencies of BL-S640, cephalothin, cefazolin, and cephalexin were compared (Table 5) . BL-S640 demonstrated generally equivalent or greater activity than cefazolin, cephalothin, or cephalexin against Klebsiella, Proteus, and E. coli. All four cephalosporins had minimal or no activity against most strains of Pseudomonas, Enterobacter, Serratia, and Providencia (not shown). Although inhibitory concentrations of cefazolin and cephalothin were consistently two-to fourfold less than BL-S640 against methicillin-susceptible staphylococci, cephalexin was notably less potent than BL-S640 against this microorganism.
The selection of microorganisms resistant to BL-S640 after serial passage in increasing concentrations of BL-S640 occurred readily as depicted by results with representative strains (Table 6 ). With the exception of strains of S. aureus, the increased resistance to cephalexin and cephalothin paralleled selection of resistance to BL-S640.
An unexpected development of resistance to cephalothin with many strains of Klebsiella was examined in more detail ( For example, Klebsiella strain no. 73-284 (Table  7) reverted to the susceptibility of the parent strain by the sixth passage in broth without added BL-S640. In contrast, Klebsiella strain no. 73-241 maintained its high level of resistance through 10 such passages.
DISCUSSION
The in vitro antimicrobial spectrum of BL-S640 was shown to be similar to other (3, 10) . In addition, greater activity of BL-S640 against staphylococci, E. coli, and Klebsiella microorganisms as compared to cephalexin was demonstrated in this study. In preliminary in vitro studies, MICs four-to eightfold less were obtained with BL-S640 than with cephalexin with strains from these genera (2) . This magnitude of difference in potency between BL-S640 and cephalexin was not consistently present in this study. In both studies, inocula sizes and media were comparable and the difference in results can not be explained by a variation in these factors.
Development of cross-resistance between BL-S640 and other cephalosporins was demonstrated. Among strains of staphylococci, resistance acquired to BL-S640 paralleled resistance to cephalothin and cephalexin; the same was true for strains of Proteus and E. coli. The stability of acquired resistance for most strains was variable. In contrast, strains of Klebsiella retained their susceptibility after multiple passages in BL-S640 despite the frequent development of resistance to cephalothin, cephalexin, or cefazolin. The mechanism for this differential selection of resistance is unexplained, and requires further study. This phenomenon could occur more frequently than previously appreciated since only those bacterial strains demonstrating resistance against one cephalosporin are routinely chosen for cross-resistance studies.
In pharmacologic studies with BL-S640 propylene glycolate, absorption after oral administration has been demonstrated (1). The preliminary comparative studies with BL-S640 and cephalexin in animals indicated that BL-S640 was absorbed slower, achieved lower peak levels, and had a longer half-life than cephalexin. Further studies in adult male volunteers demonstrated that peak concentrations of 5 to 7 and 11 to 12 ,g of BL-S640 per ml can be obtained at 1 to 2 h after doses of 0.50 and 1.0 g, respectively, of BL-S640 propylene glycolate. A pharmacological half-life of approximately 1.5 h for BL-S640 was calculated. In parallel oral absorption studies in humans, cephalexin yielded peak serum concentrations four times higher than BL-S640 and total absorption of cephalexin was superior as reflected by areas under absorption curves. Higher concentrations were attained in the urine in the first 24 h after oral administration of cephalexin, and approximately 90% of this antibiotic was recovered in the urine. This was contrasted to the recovery of only 20% of a given dose of BL-S640 in the urine in 24 h. However, 10 of 16 subjects had detectable levels of BL-S640 in the urine for >48 h.
In summary, studies with BL-S640 have confirmed its broad antimicrobial spectrum, which is similar to other cephalosporins. Preliminary pharmacological studies demonstrating lesser peak serum levels and more prolonged urinary concentrations than cephalexin suggest that BL-S640 may be useful as an oral agent for the treatment of urinary tract infections. The potentially greater antimicrobial potency of BL-S640 compared to other presently available oral agents is promising and may warrant further evaluation of the use of BL-S640 in systemic infections. The significance of these in vitro data of antimicrobial activity must be correlated with subsequent studies of pharmacokinetics as well as studies of efficacy in experimental or clinical infections.
